Tuberculosis Research Materials and Vaccine Testing

结核病研究材料和疫苗测试

• 批准号: 8083020
• 负责人: KAREN DOBOS
• 金额: $ 100万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-24 至 2011-09-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8083020
• 关键词: Adjuvant; Animal Model; Basic Science; Cell Fraction; Cells; Contracts; DNA Microarray Chip; Feasibility Studies; Genomics; Nucleic Acids; Quality Control; Reagent; Research; Research Personnel; Tuberculosis; Tuberculosis Vaccines; mycobacterial; vaccine candidate; vaccine development; vaccine evaluation

The Tuberculosis Research Materials and Vaccine Testing contract provides researchers with quality-controlled mycobacterial reagents, which includes whole cells, cell fractions, nucleic acids, and post-genomic reagents such as DNA microarrays. It also supports feasibility studies of TB vaccine candidates and adjuvants in well-characterized animal models.

结核病研究材料和疫苗测试合同为研究人员提供质量控制的分枝杆菌试剂，其中包括全细胞，细胞组分，核酸和后基因组试剂，如DNA微阵列。它还支持在特征明确的动物模型中进行结核病候选疫苗和佐剂的可行性研究。